Article
Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction.
Institut für Klinische Chemie und Laboratoriumsdiagnostik, Universitätsklinikum Jena, Jena, Germany.
Blood Coagulation and Fibrinolysis (impact factor:
1.24).
07/2008;
19(4):288-93.
DOI:10.1097/MBC.0b013e3282fe73ec
pp.288-93
Source: PubMed
-
Citations (0)
-
Cited In (0)
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
activated partial thromboplastin time
argatroban concentrations
Argatroban interference
batroxobin time
different coagulation tests
different subgroups
healthy individuals
in-vivo fibrinogen function
induced platelet aggregation
liver dysfunction
low-argatroban concentrations
oral anticoagulation therapy
patient subgroups
preexisting factor deficiency
protein S
prothrombin time
routine laboratory coagulation tests
standard laboratory coagulation tests
strong influence
thrombin time